These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34592699)
21. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475 [TBL] [Abstract][Full Text] [Related]
22. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. Villa D; Seshadri T; Puig N; Massey C; Tsang R; Keating A; Crump M; Kuruvilla J Haematologica; 2012 May; 97(5):751-7. PubMed ID: 22180434 [TBL] [Abstract][Full Text] [Related]
23. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862 [TBL] [Abstract][Full Text] [Related]
24. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. Kruger PC; Cooney JP; Turner JH Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193 [TBL] [Abstract][Full Text] [Related]
25. Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country. Carranza J; Fatobene G; Otuyama LJ; Dos Santos JG; Cordeiro AC; Mariano L; Rocha V Transplant Cell Ther; 2024 Oct; 30(10):1003.e1-1003.e9. PubMed ID: 39097096 [TBL] [Abstract][Full Text] [Related]
26. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453 [TBL] [Abstract][Full Text] [Related]
27. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368 [TBL] [Abstract][Full Text] [Related]
28. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830 [TBL] [Abstract][Full Text] [Related]
29. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas. Ji J; Liu Z; Kuang P; Dong T; Chen X; Li J; Zhang C; Liu J; Zhang L; Shen K; Liu T Int J Cancer; 2021 Dec; 149(12):2075-2082. PubMed ID: 34398971 [TBL] [Abstract][Full Text] [Related]
30. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523 [TBL] [Abstract][Full Text] [Related]
31. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722 [TBL] [Abstract][Full Text] [Related]
32. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Argiris A; Seropian S; Cooper DL Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053 [TBL] [Abstract][Full Text] [Related]
33. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. Singer S; Sharma N; Dean R; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S; Andritsos L; Vasu S; Jaglowski S; William BM; Bolwell B; Pohlman B; Kalaycio M; Jagadeesh D; Hill B; Sobecks R; Devine SM; Majhail NS; Efebera YA Bone Marrow Transplant; 2019 Oct; 54(10):1553-1561. PubMed ID: 30718797 [TBL] [Abstract][Full Text] [Related]
34. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762 [TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M Med Oncol; 2013; 30(3):611. PubMed ID: 23702734 [TBL] [Abstract][Full Text] [Related]
36. Peripheral blood stem cells mobilization in patients with relapsed or refractory lymphomas: A single-center experience. Halacoglu A; Serefhanoglu S J Cancer Res Ther; 2024 Apr; 20(3):904-908. PubMed ID: 38102912 [TBL] [Abstract][Full Text] [Related]
37. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161 [TBL] [Abstract][Full Text] [Related]
38. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Harris RE; Termuhlen AM; Smith LM; Lynch J; Henry MM; Perkins SL; Gross TG; Warkentin P; Vlachos A; Harrison L; Cairo MS Biol Blood Marrow Transplant; 2011 Feb; 17(2):249-58. PubMed ID: 20637881 [TBL] [Abstract][Full Text] [Related]
39. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795 [TBL] [Abstract][Full Text] [Related]
40. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients. Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]